GetTopicDetailResponse(id=744ae5710f, topicName=FOLFIRI方案, introduction=FOLFIRI方案, content=null, image=null, comments=4, allHits=1322, url=https://h5.medsci.cn/topic?id=7571, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=5819, tagList=[TagDto(tagId=5819, tagName=FOLFIRI方案)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1674602, encodeId=444a16e4602e9, content=<a href='/topic/show?id=744ae5710f' target=_blank style='color:#2F92EE;'>#FOLFIRI方案#</a>, objectTitle=Ther Adv Med Oncol：國(guó)內(nèi)多中心頭對(duì)頭III期研究發(fā)現(xiàn)轉(zhuǎn)移性結(jié)直腸癌患者二線FOLFIRI方案并不優(yōu)于單藥伊立替康治療，反而毒性增加, objectType=article, longId=294046, objectId=01c32940469c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01c32940469c, replyNumber=0, likeNumber=122, createdTime=2022-10-22, rootId=0, userName=yahu, userId=19da27021295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01c32940469c, moduleTitle=Ther Adv Med Oncol：國(guó)內(nèi)多中心頭對(duì)頭III期研究發(fā)現(xiàn)轉(zhuǎn)移性結(jié)直腸癌患者二線FOLFIRI方案并不優(yōu)于單藥伊立替康治療，反而毒性增加, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=01c32940469c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674601, encodeId=0c1316e460130, content=<a href='/topic/show?id=744ae5710f' target=_blank style='color:#2F92EE;'>#FOLFIRI方案#</a>, objectTitle=CLIN CANCER RES：Duligotuzumab聯(lián)合FOLFIRI方案治療RAS野生型轉(zhuǎn)移性結(jié)直腸癌, objectType=article, longId=139634, objectId=060d13963424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=060d13963424, replyNumber=0, likeNumber=102, createdTime=2019-03-26, rootId=0, userName=yahu, userId=19da27021295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=060d13963424, moduleTitle=CLIN CANCER RES：Duligotuzumab聯(lián)合FOLFIRI方案治療RAS野生型轉(zhuǎn)移性結(jié)直腸癌, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=060d13963424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674600, encodeId=2fa716e46003f, content=<a href='/topic/show?id=744ae5710f' target=_blank style='color:#2F92EE;'>#FOLFIRI方案#</a>, objectTitle=CCC：帕尼單抗或貝伐單抗聯(lián)合FOLFIRI方案二線治療轉(zhuǎn)移性結(jié)直腸癌療效比較(SPIRITT研究）, objectType=article, longId=45314, objectId=88b5453142a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88b5453142a, replyNumber=0, likeNumber=101, createdTime=2015-03-05, rootId=0, userName=yahu, userId=19da27021295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88b5453142a, moduleTitle=CCC：帕尼單抗或貝伐單抗聯(lián)合FOLFIRI方案二線治療轉(zhuǎn)移性結(jié)直腸癌療效比較(SPIRITT研究）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=88b5453142a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1674599, encodeId=605416e4599fc, content=<a href='/topic/show?id=744ae5710f' target=_blank style='color:#2F92EE;'>#FOLFIRI方案#</a>, objectTitle=JCO：舒尼替尼聯(lián)合FOLFIRI方案不優(yōu)于FOLFIRI單獨(dú)治療結(jié)直腸癌, objectType=article, longId=16827, objectId=71611682ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=71611682ee7, replyNumber=0, likeNumber=95, createdTime=2013-11-28, rootId=0, userName=yahu, userId=19da27021295, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=71611682ee7, moduleTitle=JCO：舒尼替尼聯(lián)合FOLFIRI方案不優(yōu)于FOLFIRI單獨(dú)治療結(jié)直腸癌, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=71611682ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
